GOTHENBURG, Sweden, April 28, 2023 /PRNewswire/ -- Zinzino AB (publ.) announces that the company's annual report for 2022 in Swedish is now published on the company's website, zinzino.com. The English version will be published within approximately 45 days.
The 2023 Annual General Meeting will be held at the company's premises at Hulda Mellgrens gata 5 in Västra Frölunda on May 31 at 1:30 p.m. The nomination committee's proposals for board members, the board's remuneration and auditors are presented in the notice to the annual general meeting. For further information about the annual general meeting, refer to the company's website www.zinzino.com.
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community. Aspire Health experienced a data security incident that may have involved personal and...
